Background and Purpose—The purpose of these guidelines is to provide an up-to-date
comprehensive set of recommendations in a single document for clinicians caring for adult …

Stroke is the second highest cause of death globally and a leading cause of disability, with
an increasing incidence in develo** countries. Ischaemic stroke caused by arterial …

Intravenous thrombolysis is the only approved systemic reperfusion treatment for patients
with acute ischaemic stroke. These European Stroke Organisation (ESO) guidelines provide …

Background Tenecteplase is an effective thrombolytic agent for eligible patients with stroke
who are treated within 4.5 hours after the onset of stroke. However, data regarding the …

Importance Stroke is the fifth leading cause of death and a leading cause of disability in the
United States, affecting nearly 800 000 individuals annually. Observations Sudden …

Background There is increasing interest in replacing alteplase with tenecteplase as the
preferred thrombolytic treatment for patients with acute ischaemic stroke. We aimed to …

Background Thrombolytic agents, including tenecteplase, are generally used within 4.5
hours after the onset of stroke symptoms. Information on whether tenecteplase confers …

Objectives: Concise “synthetic” review of the state of the art of management of acute
ischemic stroke. Data Sources: Available literature on PubMed. Study Selection: We …

Background Mechanical thrombectomy (MT) has become the cornerstone of acute ischemic
stroke management in patients with large vessel occlusion (LVO). Objective To assist …

Background In acute ischemic stroke, there is uncertainty regarding the benefit and risk of
administering intravenous alteplase before endovascular thrombectomy. Methods We …